Patent 12110276 was granted and assigned to Genentech on October, 2024 by the United States Patent and Trademark Office.
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.